Search

Your search keyword '"Schloegelhofer, M"' showing total 50 results
Start Over Author "Schloegelhofer, M"

Refine your results

50 results on '"Schloegelhofer, M"'

1. Basic symptoms in young people at ultra-high risk of psychosis: Association with clinical characteristics and outcomes

Author

Youn, S., Phillips, L.J., Amminger, G.P., Berger, G., Chen, E.Y.H., de Haan, L., Hartmann, J.A., Hickie, I.B., Lavoie, S., Markulev, C., McGorry, P.D., Mossaheb, N., Nieman, D.H., Nordentoft, M., Riecher-Rössler, A., Schäfer, M.R., Schlögelhofer, M., Smesny, S., Thompson, A., Verma, S., Yuen, H.P., Yung, A.R., and Nelson, B.

Published
2020
Full Text
View/download PDF

2. Dynamic prediction of transition to psychosis using joint modelling

Author

Yuen, H.P., Mackinnon, A., Hartmann, J., Amminger, G.P., Markulev, C., Lavoie, S., Schäfer, M.R., Polari, A., Mossaheb, N., Schlögelhofer, M., Smesny, S., Hickie, I.B., Berger, G., Chen, E.Y.H., de Haan, L., Nieman, D.H., Nordentoft, M., Riecher-Rössler, A., Verma, S., Thompson, A., Yung, A.R., McGorry, P.D., and Nelson, B.

Published
2018
Full Text
View/download PDF

4. Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A)

Author

Solmi, M, Estradé, A, Thompson, T, Agorastos, A, Radua, J, Cortese, S, Dragioti, E, Leisch, F, Vancampfort, D, Thygesen, LC, Aschauer, H, Schloegelhofer, M, Akimova, E, Schneeberger, A, Huber, CG, Hasler, G, Conus, P, Cuénod, KQD, von Känel, R, Arrondo, G, Fusar-Poli, P, Gorwood, P, Llorca, PM, Krebs, MO, Scanferla, E, Kishimoto, T, Rabbani, G, Skonieczna-Żydecka, K, Brambilla, P, Favaro, A, Takamiya, A, Zoccante, L, Colizzi, M, Bourgin, J, Kamiński, K, Moghadasin, M, Seedat, S, Matthews, E, Wells, J, Vassilopoulou, E, Gadelha, A, Su, KP, Kwon, JS, Kim, M, Lee, TY, Papsuev, O, Manková, D, Boscutti, A, Gerunda, C, Saccon, D, Righi, E, Monaco, F, Croatto, G, Cereda, G, Demurtas, J, Brondino, N, Veronese, N, Enrico, P, Politi, P, Ciappolino, V, Pfennig, A, Bechdolf, A, Meyer-Lindenberg, A, Kahl, KG, Domschke, K, Bauer, M, Koutsouleris, N, Winter, S, Borgwardt, S, Bitter, I, Balazs, J, Czobor, P, Unoka, Z, Mavridis, D, Tsamakis, K, Bozikas, VP, Tunvirachaisakul, C, Maes, M, Rungnirundorn, T, Supasitthumrong, T, Haque, A, Brunoni, AR, Costardi, CG, Schuch, FB, Polanczyk, G, Luiz, JM, Fonseca, L, Aparicio, LV, Valvassori, SS, Nordentoft, M, Vendsborg, P, Hoffmann, SH, Sehli, J, Sartorius, N, Heuss, S, Guinart, D, Hamilton, J, Kane, J, Rubio, J, Sand, M, Marx, Wolf, Solmi, M, Estradé, A, Thompson, T, Agorastos, A, Radua, J, Cortese, S, Dragioti, E, Leisch, F, Vancampfort, D, Thygesen, LC, Aschauer, H, Schloegelhofer, M, Akimova, E, Schneeberger, A, Huber, CG, Hasler, G, Conus, P, Cuénod, KQD, von Känel, R, Arrondo, G, Fusar-Poli, P, Gorwood, P, Llorca, PM, Krebs, MO, Scanferla, E, Kishimoto, T, Rabbani, G, Skonieczna-Żydecka, K, Brambilla, P, Favaro, A, Takamiya, A, Zoccante, L, Colizzi, M, Bourgin, J, Kamiński, K, Moghadasin, M, Seedat, S, Matthews, E, Wells, J, Vassilopoulou, E, Gadelha, A, Su, KP, Kwon, JS, Kim, M, Lee, TY, Papsuev, O, Manková, D, Boscutti, A, Gerunda, C, Saccon, D, Righi, E, Monaco, F, Croatto, G, Cereda, G, Demurtas, J, Brondino, N, Veronese, N, Enrico, P, Politi, P, Ciappolino, V, Pfennig, A, Bechdolf, A, Meyer-Lindenberg, A, Kahl, KG, Domschke, K, Bauer, M, Koutsouleris, N, Winter, S, Borgwardt, S, Bitter, I, Balazs, J, Czobor, P, Unoka, Z, Mavridis, D, Tsamakis, K, Bozikas, VP, Tunvirachaisakul, C, Maes, M, Rungnirundorn, T, Supasitthumrong, T, Haque, A, Brunoni, AR, Costardi, CG, Schuch, FB, Polanczyk, G, Luiz, JM, Fonseca, L, Aparicio, LV, Valvassori, SS, Nordentoft, M, Vendsborg, P, Hoffmann, SH, Sehli, J, Sartorius, N, Heuss, S, Guinart, D, Hamilton, J, Kane, J, Rubio, J, Sand, M, and Marx, Wolf

Published
2022

5. The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic

Author

Solmi, M, Estradé, A, Thompson, T, Agorastos, A, Radua, J, Cortese, S, Dragioti, E, Leisch, F, Vancampfort, D, Thygesen, LC, Aschauer, H, Schloegelhofer, M, Akimova, E, Schneeberger, A, Huber, CG, Hasler, G, Conus, P, Cuénod, KQD, von Känel, R, Arrondo, G, Fusar-Poli, P, Gorwood, P, Llorca, PM, Krebs, MO, Scanferla, E, Kishimoto, T, Rabbani, G, Skonieczna-Żydecka, K, Brambilla, P, Favaro, A, Takamiya, A, Zoccante, L, Colizzi, M, Bourgin, J, Kamiński, K, Moghadasin, M, Seedat, S, Matthews, E, Wells, J, Vassilopoulou, E, Gadelha, A, Su, KP, Kwon, JS, Kim, M, Lee, TY, Papsuev, O, Manková, D, Boscutti, A, Gerunda, C, Saccon, D, Righi, E, Monaco, F, Croatto, G, Cereda, G, Demurtas, J, Brondino, N, Veronese, N, Enrico, P, Politi, P, Ciappolino, V, Pfennig, A, Bechdolf, A, Meyer-Lindenberg, A, Kahl, KG, Domschke, K, Bauer, M, Koutsouleris, N, Winter, S, Borgwardt, S, Bitter, I, Balazs, J, Czobor, P, Unoka, Z, Mavridis, D, Tsamakis, K, Bozikas, VP, Tunvirachaisakul, C, Maes, M, Rungnirundorn, T, Supasitthumrong, T, Haque, A, Brunoni, AR, Costardi, CG, Schuch, FB, Polanczyk, G, Luiz, JM, Fonseca, L, Aparicio, LV, Valvassori, SS, Nordentoft, M, Vendsborg, P, Hoffmann, SH, Sehli, J, Sartorius, N, Heuss, S, Guinart, D, Hamilton, J, Kane, J, Rubio, J, Sand, M, Berk, Michael, Solmi, M, Estradé, A, Thompson, T, Agorastos, A, Radua, J, Cortese, S, Dragioti, E, Leisch, F, Vancampfort, D, Thygesen, LC, Aschauer, H, Schloegelhofer, M, Akimova, E, Schneeberger, A, Huber, CG, Hasler, G, Conus, P, Cuénod, KQD, von Känel, R, Arrondo, G, Fusar-Poli, P, Gorwood, P, Llorca, PM, Krebs, MO, Scanferla, E, Kishimoto, T, Rabbani, G, Skonieczna-Żydecka, K, Brambilla, P, Favaro, A, Takamiya, A, Zoccante, L, Colizzi, M, Bourgin, J, Kamiński, K, Moghadasin, M, Seedat, S, Matthews, E, Wells, J, Vassilopoulou, E, Gadelha, A, Su, KP, Kwon, JS, Kim, M, Lee, TY, Papsuev, O, Manková, D, Boscutti, A, Gerunda, C, Saccon, D, Righi, E, Monaco, F, Croatto, G, Cereda, G, Demurtas, J, Brondino, N, Veronese, N, Enrico, P, Politi, P, Ciappolino, V, Pfennig, A, Bechdolf, A, Meyer-Lindenberg, A, Kahl, KG, Domschke, K, Bauer, M, Koutsouleris, N, Winter, S, Borgwardt, S, Bitter, I, Balazs, J, Czobor, P, Unoka, Z, Mavridis, D, Tsamakis, K, Bozikas, VP, Tunvirachaisakul, C, Maes, M, Rungnirundorn, T, Supasitthumrong, T, Haque, A, Brunoni, AR, Costardi, CG, Schuch, FB, Polanczyk, G, Luiz, JM, Fonseca, L, Aparicio, LV, Valvassori, SS, Nordentoft, M, Vendsborg, P, Hoffmann, SH, Sehli, J, Sartorius, N, Heuss, S, Guinart, D, Hamilton, J, Kane, J, Rubio, J, Sand, M, and Berk, Michael

Published
2022

6. Do schizotypal or borderline personality disorders predict onset of psychotic disorder or persistent attenuated psychotic symptoms in patients at high clinical risk?

Author

Hadar, H., Zhang, H., Phillips, L.J., Amminger, G.P., Berger, G.E., Chen, E.Y.H., de Haan, L., Hartmann, J.A., Hickie, I.B., Lavoie, S., Markulev, C., McGorry, P.D., Mossaheb, N., Nieman, D.H., Nordentoft, M., Riecher-Rössler, A., Schäfer, M.R., Schlögelhofer, M., Smesny, S., Thompson, A., Verma, S., Yuen, H.P., Yung, A.R., and Nelson, B.

Published
2020
Full Text
View/download PDF

7. The association between migrant status and transition in an ultra-high risk for psychosis population

Author

O'Donoghue, B, Geros, H, Sizer, H, Addington, J, Amminger, GP, Beaden, CE, Cadenhead, KS, Cannon, TD, Cornblatt, BA, Berger, GE, Chen, EYH, de Haan, L, Hartmann, JA, Hickie, IB, Ising, HK, Lavoie, S, Lin, A, Markulev, C, Mathalon, DH, McGlashan, TH, Mifsud, NG, Mossaheb, N, Nieman, DH, Nordentoft, M, Perkins, DO, Riecher-Roessler, A, Schaefer, MR, Schloegelhofer, M, Seidman, LJ, Smesny, S, Thompson, A, Tsuang, MT, van der Gaag, M, Verma, S, Walker, EF, Wood, SJ, Woods, SW, Yuen, HP, Yung, AR, McGorry, PD, Nelson, B, O'Donoghue, B, Geros, H, Sizer, H, Addington, J, Amminger, GP, Beaden, CE, Cadenhead, KS, Cannon, TD, Cornblatt, BA, Berger, GE, Chen, EYH, de Haan, L, Hartmann, JA, Hickie, IB, Ising, HK, Lavoie, S, Lin, A, Markulev, C, Mathalon, DH, McGlashan, TH, Mifsud, NG, Mossaheb, N, Nieman, DH, Nordentoft, M, Perkins, DO, Riecher-Roessler, A, Schaefer, MR, Schloegelhofer, M, Seidman, LJ, Smesny, S, Thompson, A, Tsuang, MT, van der Gaag, M, Verma, S, Walker, EF, Wood, SJ, Woods, SW, Yuen, HP, Yung, AR, McGorry, PD, and Nelson, B

Abstract

PURPOSE: Migrant status is one of the most replicated and robust risk factors for developing a psychotic disorder. This study aimed to determine whether migrant status in people identified as Ultra-High Risk for Psychosis (UHR) was associated with risk of transitioning to a full-threshold psychotic disorder. METHODS: Hazard ratios for the risk of transition were calculated from five large UHR cohorts (n = 2166) and were used to conduct a meta-analysis using the generic inverse-variance method using a random-effects model. RESULTS: 2166 UHR young people, with a mean age of 19.1 years (SD ± 4.5) were included, of whom 221 (10.7%) were first-generation migrants. A total of 357 young people transitioned to psychosis over a median follow-up time of 417 days (I.Q.R.147-756 days), representing 17.0% of the cohort. The risk of transition to a full-threshold disorder was not increased for first-generation migrants, (HR = 1.08, 95% CI 0.62-1.89); however, there was a high level of heterogeneity between studies The hazard ratio for second-generation migrants to transition to a full-threshold psychotic disorder compared to the remainder of the native-born population was 1.03 (95% CI 0.70-1.51). CONCLUSIONS: This meta-analysis did not find a statistically significant association between migrant status and an increased risk for transition to a full-threshold psychotic disorder; however, several methodological issues could explain this finding. Further research should focus on examining the risk of specific migrant groups and also ensuring that migrant populations are adequately represented within UHR clinics.

Published
2021

8. Omega-3 fatty acids and neurocognitive ability in young people at ultra-high risk for psychosis

Author

McLaverty, A, Allott, KA, Berger, M, Hester, R, McGorry, PD, Nelson, B, Markulev, C, Yuen, HP, Schaefer, MR, Mossaheb, N, Schloegelhofer, M, Smesny, S, Hickie, IB, Berger, GE, Chen, EYH, de Haan, L, Nieman, DH, Nordentoft, M, Riecher-Roessler, A, Verma, S, Thompson, A, Yung, AR, Amminger, GP, McLaverty, A, Allott, KA, Berger, M, Hester, R, McGorry, PD, Nelson, B, Markulev, C, Yuen, HP, Schaefer, MR, Mossaheb, N, Schloegelhofer, M, Smesny, S, Hickie, IB, Berger, GE, Chen, EYH, de Haan, L, Nieman, DH, Nordentoft, M, Riecher-Roessler, A, Verma, S, Thompson, A, Yung, AR, and Amminger, GP

Abstract

BACKGROUND: Neurocognitive impairments are core early features of psychosis and are observed in those at ultra-high risk (UHR) for psychosis. The aim of the present study was to explore whether neurocognition is associated with polyunsaturated fatty acids (PUFAs), as has been observed in other clinical populations. METHOD: Erythrocyte levels of total omega-3-and omega-6 PUFAs the omega-3/omega-6 ratio, were measured in 265 UHR individuals. Six domains of neurocognition as well a Composite Score, were assessed using the Brief Assessment of Cognition in Schizophrenia. Pearson's correlations were used to assess the relationship between PUFAs and neurocognition. All analyses were controlled for tobacco smoking. RESULTS: Verbal Fluency correlated positively with eicosapentaenoic acid (P = .024) and alpha-linolenic acid (P = .01), and negatively with docosahexanoic acid (P = .007) and Working Memory positively correlated with omega-3/omega-6 ratio (P = .007). CONCLUSIONS: The current results provide support for a relationship between Verbal Fluency and omega-3 PUFAs in UHR. Further investigation is required to elucidate whether these biomarkers are useful as risk markers or in understanding the biological underpinning of neurocognitive impairment in this population.

Published
2021

9. Basic symptoms in young people at ultra-high risk of psychosis: Association with clinical characteristics and outcomes

Author

Youn, S, Phillips, LJ, Amminger, GP, Berger, G, Chen, EYH, de Haan, L, Hartmann, JA, Hickie, IB, Lavoie, S, Markulev, C, McGorry, PD, Mossaheb, N, Nieman, DH, Nordentoft, M, Riecher-Rossler, A, Schafer, MR, Schloegelhofer, M, Smesny, S, Thompson, A, Verma, S, Yuen, HP, Yung, AR, Nelson, B, Youn, S, Phillips, LJ, Amminger, GP, Berger, G, Chen, EYH, de Haan, L, Hartmann, JA, Hickie, IB, Lavoie, S, Markulev, C, McGorry, PD, Mossaheb, N, Nieman, DH, Nordentoft, M, Riecher-Rossler, A, Schafer, MR, Schloegelhofer, M, Smesny, S, Thompson, A, Verma, S, Yuen, HP, Yung, AR, and Nelson, B

Abstract

There has been limited research into the predictive value of basic symptoms and their relationship with other psychopathology in patients identified using the 'ultra high risk' (UHR) for psychosis approach. The current study investigated whether basic symptoms, specifically cognitive disturbances (COGDIS), were associated with a greater risk of transition to psychotic disorder and persistent attenuated psychotic symptoms (APS) at medium term follow-up (mean = 3.4 years) in UHR patients, as well as with general psychopathology at baseline. The sample included 304 UHR participants (mean age = 19.12 years) involved in an international multicenter trial of omega-3 fatty acids. UHR individuals who also met the COGDIS criteria (basic symptoms risk criteria) did not have a greater risk of transition than those who met the UHR criteria alone. However, meeting COGDIS risk criteria was associated with a greater likelihood of meeting the UHR attenuated psychotic symptoms risk group (i.e., having persistent attenuated psychotic symptoms) at 12-month follow-up (odds ratio = 1.85; 95% CI = 1.03, 3.32). Greater severity of cognitive basic symptoms was also independently associated with more severe general psychopathology at study entry. The findings do not support the notion that combined risk identification approaches (UHR and basic symptoms) aid in the identification of individuals at greatest risk of psychosis, although this interpretation is limited by the modest transition to psychosis rate (13%) and the time of follow up. However, the findings indicate that basic symptoms may be a clinically useful marker of more severe general psychopathology in UHR groups and risk for persistent attenuated psychotic symptoms.

Published
2020

10. Do schizotypal or borderline personality disorders predict onset of psychotic disorder or persistent attenuated psychotic symptoms in patients at high clinical risk?

Author

Hadar, H, Zhang, H, Phillips, LJ, Amminger, GP, Berger, GE, Chen, EYH, de Haan, L, Hartmann, JA, Hickie, IB, Lavoie, S, Markulev, C, McGorry, PD, Mossaheb, N, Nieman, DH, Nordentoft, M, Riecher-Rossler, A, Schafer, MR, Schloegelhofer, M, Smesny, S, Thompson, A, Verma, S, Yuen, HP, Yung, AR, Nelson, B, Hadar, H, Zhang, H, Phillips, LJ, Amminger, GP, Berger, GE, Chen, EYH, de Haan, L, Hartmann, JA, Hickie, IB, Lavoie, S, Markulev, C, McGorry, PD, Mossaheb, N, Nieman, DH, Nordentoft, M, Riecher-Rossler, A, Schafer, MR, Schloegelhofer, M, Smesny, S, Thompson, A, Verma, S, Yuen, HP, Yung, AR, and Nelson, B

Published
2020

11. Cognitive functioning in ultra -high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial

Author

Mallawaarachchi, SR, Amminger, GP, Farhall, J, Bolt, LK, Nelson, B, Yuen, HP, McGorry, PD, Markulev, C, Schaefer, MR, Mossaheb, N, Schloegelhofer, M, Smesny, S, Hickie, IB, Berger, GE, Chen, EYH, de Haan, L, Nieman, DH, Nordentoft, M, Riecher-Roessler, A, Verma, S, Thompson, A, Yung, AR, Allott, KA, Mallawaarachchi, SR, Amminger, GP, Farhall, J, Bolt, LK, Nelson, B, Yuen, HP, McGorry, PD, Markulev, C, Schaefer, MR, Mossaheb, N, Schloegelhofer, M, Smesny, S, Hickie, IB, Berger, GE, Chen, EYH, de Haan, L, Nieman, DH, Nordentoft, M, Riecher-Roessler, A, Verma, S, Thompson, A, Yung, AR, and Allott, KA

Abstract

Neurocognitive impairments are well established in both ultra-high risk (UHR) for psychosis and major depressive disorder (MDD). Despite this understanding, investigation of neurocognitive deficits in UHR individuals with MDD and its association with MDD within this population, has been scarce. Hence, this study aimed to examine any differences in neurocognition at baseline between those with MDD at baseline and those with no history of MDD, as well as determine whether neurocognitive variables are significantly associated with meeting criteria for MDD at follow-up, while controlling for relevant clinical variables, within a UHR cohort. Data analysis was conducted on 207 participants whose baseline neurocognition was assessed using Brief Assessment of Cognition for Schizophrenia, as part of a trial of omega-3 fatty acids (NEURAPRO) for UHR individuals. While baseline MDD was the strongest predictor, poorer verbal memory and higher verbal fluency were significantly associated with MDD at 12 months (p = .04 and 0.026, respectively). Further, higher processing speed was significantly associated with MDD at medium-term follow-up (p = .047). These findings outline that neurocognitive skills were independently associated with meeting criteria for MDD at follow-up within UHR individuals, with novel findings of better verbal fluency and processing speed being linked to MDD outcomes. Hence, neurocognitive performance should be considered as a marker of risk for MDD outcomes and a target for management of MDD in UHR.

Published
2020

12. Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial (vol 10, 393, 2019)

Author

Berger, M, Nelson, B, Markulev, C, Yuen, HP, Schafer, MR, Mossaheb, N, Schloegelhofer, M, Smesny, S, Hickie, IB, Berger, GE, Chen, EYH, de Haan, L, Nieman, DH, Nordentoft, M, Riecher-Roessler, A, Verma, S, Mitchell, TW, Meyer, BJ, Thompson, A, Yung, AR, McGorry, PD, Amminger, GP, Berger, M, Nelson, B, Markulev, C, Yuen, HP, Schafer, MR, Mossaheb, N, Schloegelhofer, M, Smesny, S, Hickie, IB, Berger, GE, Chen, EYH, de Haan, L, Nieman, DH, Nordentoft, M, Riecher-Roessler, A, Verma, S, Mitchell, TW, Meyer, BJ, Thompson, A, Yung, AR, McGorry, PD, and Amminger, GP

Abstract

[This corrects the article DOI: 10.3389/fpsyt.2019.00393.].

Published
2020

13. Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial

Author

Berger, M, Nelson, B, Markulev, C, Yuen, HP, Schafer, MR, Mossaheb, N, Schloegelhofer, M, Smesny, S, Hickie, IB, Berger, GE, Chen, EYH, de Haan, L, Nieman, DH, Nordentoft, M, Riecher-Rossler, A, Verma, S, Thompson, A, Yung, AR, McGorry, PD, Amminger, GP, Berger, M, Nelson, B, Markulev, C, Yuen, HP, Schafer, MR, Mossaheb, N, Schloegelhofer, M, Smesny, S, Hickie, IB, Berger, GE, Chen, EYH, de Haan, L, Nieman, DH, Nordentoft, M, Riecher-Rossler, A, Verma, S, Thompson, A, Yung, AR, McGorry, PD, and Amminger, GP

Abstract

Background: Deficiencies in membrane polyunsaturated fatty acids (PUFA) such as omega-3 (n-3) fatty acids are thought to contribute to the pathophysiological processes underlying psychotic disorders. Emerging evidence suggests that the levels of PUFA are related to clinical symptoms but significant heterogeneity exists between studies. Here, we investigated associations of membrane PUFA with clinical symptoms and functioning in a large sample of individuals at ultra-high risk (UHR) for psychosis. Methods: A total of 285 participants of the NEURAPRO clinical trial were investigated for erythrocyte PUFA levels, including the n-3 index, n-6/n-3 PUFA ratio, docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA). Severity of general psychopathology [Brief Psychiatric Rating Scale (BPRS)], psychotic symptoms (BPRS psychosis subscale), negative symptoms [Scale for the Assessment of Negative Symptoms (SANS)], manic symptoms [Young Mania Rating Scale (YMRS)], depressive symptoms [Montgomery Asberg Depression Rating Scale (MADRS)], and functioning [Social and Occupational Functioning Scale (SOFAS), Global Functioning Social (GF-S) and Role (GF-R) scales] were assessed concurrently. Partial correlation taking into account the effects of gender, age, and smoking was used to examine the relationship between PUFAs and symptoms severity. Results: The n-3 index negatively correlated with the severity of general psychopathology, psychotic symptoms, depressive symptoms, and manic symptoms. The n-6/n-3 PUFA ratio positively correlated with severity of psychotic and depressive symptoms. The n-3 PUFA DHA negatively correlated with the severity of general psychopathology, positive, manic, and depressive symptoms. EPA negatively correlated with manic symptoms. Nervonic acid, an n-9 monounsaturated fatty acid, positively correlated with general psychopathology, positive and negative symptoms, depressive symptoms, and manic symptoms. The long-chain saturated fatty acid tetracosanoic ac

Published
2019

14. Usefulness of the CAPE-P15 for detecting people at ultra-high risk for psychosis: Psychometric properties and cut-off values

Author

Bukenaite, A, Stochl, J, Mossaheb, N, Schäfer, MR, Klier, CM, Becker, J, Schloegelhofer, M, Papageorgiou, K, Montejo, AL, Russo, DA, Jones, PB, Perez, J, Amminger, GP, Stochl, Jan [0000-0002-9693-9930], Jones, Peter [0000-0002-0387-880X], and Apollo - University of Cambridge Repository

Subjects
CAARMS, screening, education, CAPE-P15, psychosis, CAPE, ultra-high risk
Abstract

A need for a brief, easy to complete self-report questionnaire to detect people at ultra-high risk for psychosis (UHR) in busy clinical settings has been recognised. Our aim was to explore whether the Community Assessment of Psychic Experiences – Positive 15-items Scale (CAPE-P15) could be used as a screening tool to identify people at UHR in a clinical setting. Our objectives were to confirm the CAPE-P15 factorial structure as well as its reliability and determine cut-off values for the detection of such individuals using the Comprehensive Assessment of At-Risk Mental States (CAARMS), a commonly used clinical interview for the detection of UHR. 165 participants aged between 13 and 18 referred to the General Hospital of Vienna were included in the analysis. 50.9% of the sample were “CAARMS-positive” and 49.1% “CAARMS-negative”. The Youden method determined CAPE-P15 cut-off values for UHR detection of 1.47 for both frequency of and distress associated with psychotic experiences. The cut-off value of 1.47 for frequency showed sensitivity of 77%, specificity of 58%, a positive predictive value of 66% and a negative predictive value of 71%; whilst for distress it showed sensitivity of 73%, specificity of 63%, a positive predictive value of 69% and a negative predictive value of 66%. Good reliability and the previously suggested three-correlated factor model as well as an alternative bi-factor model of the CAPE-P15 were confirmed. The CAPE-P15 seems to be a promising screening tool for identifying people who might be at UHR in busy clinical settings.

Published
2017
Full Text
View/download PDF

15. NEUROCOGNITION IN ULTRA-HIGHRISK INDIVIDUALS AND RELATIONSHIP TO TRANSITION TO PSYCHOSIS, DEPRESSIVE DISORDER, AND FUNCTIONING: FINDINGS FROM THE NEURAPRO TRIAL

Author

Allott, K, McGorry, P, Bolt, L, Nelson, B, Markulev, C, Yuen, HP, Schaefer, M, Mossaheb, N, Schloegelhofer, M, Smesny, S, Hickie, I, Berger, G, Chen, E, De Haan, L, Nieman, D, Nordentoft, M, Riecher-Rossler, A, Verma, S, Thompson, A, Yung, Alison, Amminger, GP, Allott, K, McGorry, P, Bolt, L, Nelson, B, Markulev, C, Yuen, HP, Schaefer, M, Mossaheb, N, Schloegelhofer, M, Smesny, S, Hickie, I, Berger, G, Chen, E, De Haan, L, Nieman, D, Nordentoft, M, Riecher-Rossler, A, Verma, S, Thompson, A, Yung, Alison, and Amminger, GP

Published
2018

16. THE NEURAPRO STUDY: ADHERENCE TO STUDY MEDICATION

Author

Schloegelhofer, M, McGorry, PD, Nelson, B, Markulev, C, Yuen, HP, Schaefer, M, Mossaheb, N, Smesny, S, Hickie, IB, Berger, G, Chen, EYH, de Haan, L, Nieman, DH, Nordentoft, M, Riecher-Roessler, A, Verma, S, Thompson, A, Yung, Alison, Amminger, GP, Schloegelhofer, M, McGorry, PD, Nelson, B, Markulev, C, Yuen, HP, Schaefer, M, Mossaheb, N, Smesny, S, Hickie, IB, Berger, G, Chen, EYH, de Haan, L, Nieman, DH, Nordentoft, M, Riecher-Roessler, A, Verma, S, Thompson, A, Yung, Alison, and Amminger, GP

Published
2018

17. Erythrocyte glutathione levels as long-term predictor of transition to psychosis

Author

Lavoie, S, Berger, M, Schloegelhofer, M, Schaefer, MR, Rice, S, Kim, S-W, Hesse, J, McGorry, PD, Smesny, S, Amminger, GP, Lavoie, S, Berger, M, Schloegelhofer, M, Schaefer, MR, Rice, S, Kim, S-W, Hesse, J, McGorry, PD, Smesny, S, and Amminger, GP

Abstract

A high proportion of individuals deemed at elevated risk for psychosis will actually never progress to develop the illness. Pharmaceutical intervention may not be necessary in these cases, and may in fact be damaging depending on the invasiveness of the treatment strategy. This highlights the need for biomarkers that are better able to reliably differentiate between at-risk individuals who will subsequently transition to psychosis and those who will not. Low glutathione (GSH) levels have been observed in schizophrenia and in patients with first-episode psychosis. The aim of this study was to determine the predictive value of erythrocyte GSH levels on the transition to psychosis in individuals at risk of developing the illness. Erythrocyte GSH levels were measured in 36 at-risk individuals, 15 of whom had transitioned to psychosis at the 7-year follow-up. Univariate Cox regression analysis showed that transition to psychosis at the 7-year time point was significantly associated with low GSH levels at baseline. The area under the receiving operating characteristic curve was 0.819, indicating that GSH can be considered a good predictor of outcome. Although these results need to be replicated, adding the criterion 'low erythrocyte GSH' to the set of criteria used to identify individuals at risk of psychosis may be indicated.

Published
2017

18. Omega-6 to omega-3 polyunsaturated fatty acid ratio and subsequent mood disorders in young people with at-risk mental states: a 7-year longitudinal study

Author

Berger, ME, Smesny, S, Kim, S-W, Davey, CG, Rice, S, Sarnyai, Z, Schloegelhofer, M, Schafer, MR, Berk, M, McGorry, PD, Amminger, GP, Berger, ME, Smesny, S, Kim, S-W, Davey, CG, Rice, S, Sarnyai, Z, Schloegelhofer, M, Schafer, MR, Berk, M, McGorry, PD, and Amminger, GP

Abstract

While cross-sectional studies suggest that patients with mood disorders have a higher ratio of omega-6 to omega-3 polyunsaturated fatty acids (PUFAs) and lower levels of omega-3 PUFAs, it is unknown if a high n-6/3 ratio indicates vulnerability for depression. We tested this hypothesis in a 7-year follow-up study of young individuals with an ultra-high risk (UHR) phenotype. We conducted a secondary analysis of the Vienna omega-3 study, a longitudinal study of omega-3 PUFAs in individuals at UHR for psychosis (n=69). Levels of n-6 and n-3 PUFAs were measured in the phosphatidylethanolamine fraction of erythrocyte membranes at intake into the study. Mood disorder diagnosis was ascertained with the Structured Clinical Interview for DSM-IV-TR and confirmed by review of medical records and interviews of caregivers. A higher n-6/3 PUFA ratio at baseline predicted mood disorders in UHR individuals over a 7-year (median) follow-up (odds ratio=1.89, 95% CI=1.075-3.338, P=0.03). This association remained significant after adjustment for age, gender, smoking, severity of depressive symptoms at baseline and n-3 supplementation. Consistent results were obtained for individual PUFAs, including lower levels of eicosapentaenoic acid and docosahexaenoic acid. The predictive capacity of these findings was specific to mood disorders as no associations were found for any other psychiatric disorder. To our knowledge, our data provide the first prospective evidence that the n-6/3 PUFA ratio is associated with an increased risk for mood disorders in young people exhibiting an UHR phenotype. These findings may have important implications for treatment and risk stratification beyond clinical characteristics.

Published
2017

19. Niacin Skin Sensitivity Is Increased in Adolescents at Ultra-High Risk for Psychosis

Author

Leweke, FM, Berger, GE, Smesny, S, Schaefer, MR, Milleit, B, Langbein, K, Hipler, U-C, Milleit, C, Klier, CM, Schloegelhofer, M, Holub, M, Holzer, I, Berk, M, McGorry, PD, Sauer, H, Amminger, GP, Leweke, FM, Berger, GE, Smesny, S, Schaefer, MR, Milleit, B, Langbein, K, Hipler, U-C, Milleit, C, Klier, CM, Schloegelhofer, M, Holub, M, Holzer, I, Berk, M, McGorry, PD, Sauer, H, and Amminger, GP

Abstract

BACKGROUND: Most studies provide evidence that the skin flush response to nicotinic acid (niacin) stimulation is impaired in schizophrenia. However, only little is known about niacin sensitivity in the ultra-high risk (UHR) phase of psychotic disorders. METHODS: We compared visual ratings of niacin sensitivity between adolescents at UHR for psychosis according to the one year transition outcome (UHR-T n = 11; UHR-NT n = 55) with healthy controls (HC n = 25) and first episode schizophrenia patients (FEP n = 25) treated with atypical antipsychotics. RESULTS: Contrary to our hypothesis niacin sensitivity of the entire UHR group was not attenuated, but significantly increased compared to the HC group, whereas no difference could be found between the UHR-T and UHR-NT groups. As expected, niacin sensitivity of FEP was attenuated compared to HC group. In UHR individuals niacin sensitivity was inversely correlated with omega-6 and -9 fatty acids (FA), but positively correlated with phospholipase A2 (inPLA2) activity, a marker of membrane lipid repair/remodelling. CONCLUSIONS: Increased niacin sensitivity in UHR states likely indicates an impaired balance of eicosanoids and omega-6/-9 FA at a membrane level. Our findings suggest that the emergence of psychosis is associated with an increased mobilisation of eicosanoids prior to the transition to psychosis possibly reflecting a "pro-inflammatory state", whereas thereafter eicosanoid mobilisation seems to be attenuated. Potential treatment implications for the UHR state should be further investigated.

Published
2016

20. Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study

Author

Amminger, GP, Schaefer, MR, Schloegelhofer, M, Klier, CM, McGorry, PD, Amminger, GP, Schaefer, MR, Schloegelhofer, M, Klier, CM, and McGorry, PD

Abstract

Long-chain omega-3 polyunsaturated fatty acids (PUFAs) are essential for neural development and function. As key components of brain tissue, omega-3 PUFAs play critical roles in brain development and function, and a lack of these fatty acids has been implicated in a number of mental health conditions over the lifespan, including schizophrenia. We have previously shown that a 12-week intervention with omega-3 PUFAs reduced the risk of progression to psychotic disorder in young people with subthreshold psychotic states for a 12-month period compared with placebo. We have now completed a longer-term follow-up of this randomized, double-blind, placebo-controlled trial, at a median of 6.7 years. Here we show that brief intervention with omega-3 PUFAs reduced both the risk of progression to psychotic disorder and psychiatric morbidity in general in this study. The majority of the individuals from the omega-3 group did not show severe functional impairment and no longer experienced attenuated psychotic symptoms at follow-up.

Published
2015

21. Association of deficits in smell identification, social and basic cognition in patients with schizophrenia-spectrum disorders, their first-degree relatives and matched healthy controls

Author

Mossaheb, N., primary, Schloegelhofer, M., additional, Kaufmann, R.M., additional, Aninilkumparambil, T., additional, Gold, A., additional, Himmelbauer, C., additional, Inreiter, S., additional, Schlehaider, L., additional, Hoffmann, H., additional, and Aschauer, H.N., additional

Published
2011
Full Text
View/download PDF

36. The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic

Author

Solmi, Marco, Estradé, Andrés, Thompson, Trevor, Agorastos, Agorastos, Radua, Joaquim, Cortese, Samuele, Dragioti, Elena, Leisch, Friedrich, Vancampfort, Davy, Thygesen, Lau Caspar, Aschauer, Harald, Schloegelhofer, Monika, Akimova, Elena, Schneeberger, Andres, Huber, Christian, Hasler, Gregor, Conus, Philippe, Cuénod, Kim, von Känel, Roland, Arrondo, Gonzalo, Fusar-Poli, Paolo, Gorwood, Philip, Llorca, Pierre-Michel, Krebs, Marie-Odile, Scanferla, Elisabetta, Kishimoto, Taishiro, Rabbani, Golam, Skonieczna-Żydecka, Karolina, Brambilla, Paolo, Favaro, Angela, Takamiya, Akihiro, Zoccante, Leonardo, Colizzi, Marco, Bourgin, Julie, Kamiński, Karol, Moghadasin, Maryam, Seedat, Soraya, Matthews, Evan, Wells, John, Vassilopoulou, Emilia, Gadelha, Ary, Su, Kuan-Pin, Kwon, Jun Soo, Kim, Minah, Lee, Tae Young, Papsuev, Oleg, Manková, Denisa, Boscutti, Andrea, Gerunda, Cristiano, Saccon, Diego, Righi, Elena, Monaco, Francesco, Croatto, Giovanni, Cereda, Guido, Demurtas, Jacopo, Brondino, Natascia, Veronese, Nicola, Enrico, Paolo, Politi, Pierluigi, Ciappolino, Valentina, Pfennig, Andrea, Bechdolf, Andreas, Meyer-Lindenberg, Andreas, Kahl, Kai, Domschke, Katharina, Bauer, Michael, Koutsouleris, Nikolaos, Winter, Sibylle, Borgwardt, Stefan, Bitter, Istvan, Balazs, Judit, Czobor, Pal, Unoka, Zsolt, Mavridis, Dimitris, Tsamakis, Konstantinos, Bozikas, Vasilios, Tunvirachaisakul, Chavit, Maes, Michael, Rungnirundorn, Teerayuth, Supasitthumrong, Thitiporn, Haque, Ariful, Brunoni, Andre, Costardi, Carlos Gustavo, Schuch, Felipe Barreto, Polanczyk, Guilherme, Luiz, Jhoanne Merlyn, Fonseca, Lais, Aparicio, Luana, Valvassori, Samira, Nordentoft, Merete, Vendsborg, Per, Hoffmann, Sofie Have, Sehli, Jihed, Sartorius, Norman, Heuss, Sabina, Guinart, Daniel, Hamilton, Jane, Kane, John, Rubio, Jose, Sand, Michael, Koyanagi, Ai, Solanes, Aleix, Andreu-Bernabeu, Alvaro, Cáceres, Antonia San José, Arango, Celso, Díaz-Caneja, Covadonga, Hidalgo-Mazzei, Diego, Vieta, Eduard, Gonzalez-Peñas, Javier, Fortea, Lydia, Parellada, Mara, Fullana, Miquel, Verdolini, Norma, Fárková, Eva, Janků, Karolina, Millan, Mark, Honciuc, Mihaela, Moniuszko-Malinowska, Anna, Łoniewski, Igor, Samochowiec, Jerzy, Kiszkiel, Łukasz, Marlicz, Maria, Sowa, Paweł, Marlicz, Wojciech, Spies, Georgina, Stubbs, Brendon, Firth, Joseph, Sullivan, Sarah, Darcin, Asli Enez, Aksu, Hatice, Dilbaz, Nesrin, Noyan, Onur, Kitazawa, Momoko, Kurokawa, Shunya, Tazawa, Yuki, Anselmi, Alejandro, Cracco, Cecilia, Machado, Ana Inés, Estrade, Natalia, de Leo, Diego, Curtis, Jackie, Berk, Michael, Ward, Philip, Teasdale, Scott, Rosenbaum, Simon, Marx, Wolfgang, Horodnic, Adrian Vasile, Oprea, Liviu, Alexinschi, Ovidiu, Ifteni, Petru, Turliuc, Serban, Ciuhodaru, Tudor, Bolos, Alexandra, Matei, Valentin, Nieman, Dorien, Sommer, Iris, van Os, Jim, van Amelsvoort, Therese, Sun, Ching-Fang, Guu, Ta-Wei, Jiao, Can, Zhang, Jieting, Fan, Jialin, Zou, Liye, Yu, Xin, Chi, Xinli, de Timary, Philippe, van Winke, Ruud, Ng, Bernardo, Pena, Edilberto, Arellano, Ramon, Roman, Raquel, Sanchez, Thelma, Movina, Larisa, Morgado, Pedro, Brissos, Sofia, Aizberg, Oleg, Mosina, Anna, Krinitski, Damir, Mugisha, James, Sadeghi-Bahmani, Dena, Sadeghi, Masoud, Hadi, Samira, Brand, Serge, Errazuriz, Antonia, Crossley, Nicolas, Ristic, Dragana Ignjatovic, López-Jaramillo, Carlos, Efthymiou, Dimitris, Kuttichira, Praveenlal, Kallivayalil, Roy Abraham, Javed, Afzal, Afridi, Muhammad Iqbal, James, Bawo, Seb-Akahomen, Omonefe Joy, Fiedorowicz, Jess, Carvalho, Andre, Daskalakis, Jeff, Yatham, Lakshmi, Yang, Lin, Okasha, Tarek, Dahdouh, Aïcha, Gerdle, Björn, Tiihonen, Jari, Shin, Jae Il, Lee, Jinhee, Mhalla, Ahmed, Gaha, Lotfi, Brahim, Takoua, Altynbekov, Kuanysh, Negay, Nikolay, Nurmagambetova, Saltanat, Jamei, Yasser Abu, Weiser, Mark, Correll, Christoph, Thygesen, Lau, Kwon, Jun, Lee, Tae, Costardi, Carlos, Schuch, Felipe, Luiz, Jhoanne, Hoffmann, Sofie, Cáceres, Antonia, Darcin, Asli, Machado, Ana, Horodnic, Adrian, Ristic, Dragana, Kallivayalil, Roy, Afridi, Muhammad, Seb-Akahomen, Omonefe, Shin, Jae, Jamei, Yasser, RS: MHeNs - R2 - Mental Health, Psychiatrie & Neuropsychologie, MUMC+: MA Med Staf Spec Psychiatrie (9), Clinical Cognitive Neuropsychiatry Research Program (CCNP), Movement Disorder (MD), Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université Paris Cité (UPCité), GHU Paris Psychiatrie et Neurosciences, Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), CHU Clermont-Ferrand, Pathologies et épithéliums : prévention, innovation, traitements, évaluation (UR 4267) (PEPITE), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Martinez Rico, Clara, Solmi, M., Estradé, A., Thompson, T., Agorastos, A., Radua, J., Cortese, S., Dragioti, E., Leisch, F., Vancampfort, D., Thygesen, L.C., Aschauer, H., Schloegelhofer, M., Akimova, E., Schneeberger, A., Huber, C.G., Hasler, G., Conus, P., Cuénod, K.Q.D., von Känel, R., Arrondo, G., Fusar-Poli, P., Gorwood, P., Llorca, P.-M., Krebs, M.-O., Scanferla, E., Kishimoto, T., Rabbani, G., Skonieczna-Żydecka, K., Brambilla, P., Favaro, A., Takamiya, A., Zoccante, L., Colizzi, M., Bourgin, J., Kamiński, K., Moghadasin, M., Seedat, S., Matthews, E., Wells, J., Vassilopoulou, E., Gadelha, A., Su, K.-P., Kwon, J.S., Kim, M., Lee, T.Y., Papsuev, O., Manková, D., Boscutti, A., Gerunda, C., Saccon, D., Righi, E., Monaco, F., Croatto, G., Cereda, G., Demurtas, J., Brondino, N., Veronese, N., Enrico, P., Politi, P., Ciappolino, V., Pfennig, A., Bechdolf, A., Meyer-Lindenberg, A., Kahl, K.G., Domschke, K., Bauer, M., Koutsouleris, N., Winter, S., Borgwardt, S., Bitter, I., Balazs, J., Czobor, P., Unoka, Z., Mavridis, D., Tsamakis, K., Bozikas, V.P., Tunvirachaisakul, C., Maes, M., Rungnirundorn, T., Supasitthumrong, T., Haque, A., Brunoni, A.R., Costardi, C.G., Schuch, F.B., Polanczyk, G., Luiz, J.M., Fonseca, L., Aparicio, L.V., Valvassori, S.S., Nordentoft, M., Vendsborg, P., Hoffmann, S.H., Sehli, J., Sartorius, N., Heuss, S., Guinart, D., Hamilton, J., Kane, J., Rubio, J., Sand, M., Koyanagi, A., Solanes, A., Andreu-Bernabeu, A., Cáceres, A.S.J., Arango, C., Díaz-Caneja, C.M., Hidalgo-Mazzei, D., Vieta, E., Gonzalez-Peñas, J., Fortea, L., Parellada, M., Fullana, M.A., Verdolini, N., Fárková, E., Janků, K., Millan, M., Honciuc, M., Moniuszko-Malinowska, A., Łoniewski, I., Samochowiec, J., Kiszkiel, Ł., Marlicz, M., Sowa, P., Marlicz, W., Spies, G., Stubbs, B., Firth, J., Sullivan, S., Darcin, A.E., Aksu, H., Dilbaz, N., Noyan, O., Kitazawa, M., Kurokawa, S., Tazawa, Y., Anselmi, A., Cracco, C., Machado, A.I., Estrade, N., De Leo, D., Curtis, J., Berk, M., Ward, P., Teasdale, S., Rosenbaum, S., Marx, W., Horodnic, A.V., Oprea, L., Alexinschi, O., Ifteni, P., Turliuc, S., Ciuhodaru, T., Bolos, A., Matei, V., Nieman, D.H., Sommer, I., van Os, J., van Amelsvoort, T., Sun, C.-F., Guu, T.-W., Jiao, C., Zhang, J., Fan, J., Zou, L., Yu, X., Chi, X., de Timary, P., van Winke, R., Ng, B., Pena, E., Arellano, R., Roman, R., Sanchez, T., Movina, L., Morgado, P., Brissos, S., Aizberg, O., Mosina, A., Krinitski, D., Mugisha, J., Sadeghi-Bahmani, D., Sadeghi, M., Hadi, S., Brand, S., Errazuriz, A., Crossley, N., Ristic, D.I., López-Jaramillo, C., Efthymiou, D., Kuttichira, P., Kallivayalil, R.A., Javed, A., Afridi, M.I., James, B., Seb-Akahomen, O.J., Fiedorowicz, J., Carvalho, A.F., Daskalakis, J., Yatham, L.N., Yang, L., Okasha, T., Dahdouh, A., Gerdle, B., Tiihonen, J., Shin, J.I., Lee, J., Mhalla, A., Gaha, L., Brahim, T., Altynbekov, K., Negay, N., Nurmagambetova, S., Jamei, Y.A., Weiser, M., Correll, C.U., Adult Psychiatry, APH - Mental Health, ANS - Compulsivity, Impulsivity & Attention, and ANS - Mood, Anxiety, Psychosis, Stress & Sleep

Subjects
Gerontology, DISORDER, STRESS, Outcome Assessment, IMPACT, [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, RA0421, well-being, Pandemic, Health care, Outcome Assessment, Health Care, adults, Medicine, ANXIETY, COVID-19, mental health, functioning, physical health, representative, resilience, survey, international, psychiatry, depression, anxiety, post-traumatic, COH-FIT, children, adolescents, mental health, functioning, physical health, representative, well-being, resilience, survey, international, psychiatry, depression, anxiety, post-traumatic, COH-FIT, children, adolescents, adult, Child, SCALE, Psychiatry, education.field_of_study, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Public Health, Global Health, Social Medicine and Epidemiology, Psychiatry and Mental health, Clinical Psychology, Professional association, Life Sciences & Biomedicine, Psychopathology, Research Paper, Adult, Coronavirus disease 2019 (COVID-19), Adolescent, Population, Clinical Neurology, BF, Anxiety, Cross-Sectional Studies, Depression, Humans, Mental Health, SARS-CoV-2, Pandemics, Intervention (counseling), MANAGEMENT, VALIDITY, education, Science & Technology, business.industry, MORTALITY, CARE, Mental health, Health Care, Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Neurosciences & Neurology, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

BACKGROUND: . High-quality comprehensive data on short-/long-term physical/mental health effects of the COVID-19 pandemic are needed. METHODS: . The Collaborative Outcomes study on Health and Functioning during Infection Times (COH-FIT) is an international, multi-language (n=30) project involving >230 investigators from 49 countries/territories/regions, endorsed by national/international professional associations. COH-FIT is a multi-wave, on-line anonymous, cross-sectional survey [wave 1: 04/2020 until the end of the pandemic, 12 months waves 2/3 starting 6/24 months threreafter] for adults, adolescents (14-17), and children (6-13), utilizing non-probability/snowball and representative sampling. COH-FIT aims to identify non-modifiable/modifiable risk factors/treatment targets to inform prevention/intervention programs to improve social/health outcomes in the general population/vulnerable subgrous during/after COVID-19. In adults, co-primary outcomes are change from pre-COVID-19 to intra-COVID-19 in well-being (WHO-5) and a composite psychopathology P-Score. Key secondary outcomes are a P-extended score, global mental and physical health. Secondary outcomes include health-service utilization/functioning, treatment adherence, functioning, symptoms/behaviors/emotions, substance use, violence, among others. RESULTS: . Starting 04/26/2020, up to 14/07/2021 >151,000 people from 155 countries/territories/regions and six continents have participated. Representative samples of ≥1,000 adults have been collected in 15 countries. Overall, 43.0% had prior physical disorders, 16.3% had prior mental disorders, 26.5% were health care workers, 8.2% were aged ≥65 years, 19.3% were exposed to someone infected with COVID-19, 76.1% had been in quarantine, and 2.1% had been COVID 19-positive. LIMITATIONS: . Cross-sectional survey, preponderance of non-representative participants. CONCLUSIONS: . Results from COH-FIT will comprehensively quantify the impact of COVID-19, seeking to identify high-risk groups in need for acute and long-term intervention, and inform evidence-based health policies/strategies during this/future pandemics. ispartof: JOURNAL OF AFFECTIVE DISORDERS vol:299 pages:393-407 ispartof: location:Netherlands status: published

Published
2022
Full Text
View/download PDF

37. Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times-Children and Adolescents (COH-FIT-C&A)

Author

Solmi, Marco, Estradé, Andrés, Thompson, Trevor, Agorastos, Agorastos, Radua, Joaquim, Cortese, Samuele, Dragioti, Elena, Leisch, Friedrich, Vancampfort, Davy, Thygesen, Lau Caspar, Aschauer, Harald, Schloegelhofer, Monika, Akimova, Elena, Schneeberger, Andres, Huber, Christian, Hasler, Gregor, Conus, Philippe, Cuénod, Kim, von Känel, Roland, Arrondo, Gonzalo, Fusar-Poli, Paolo, Gorwood, Philip, Llorca, Pierre-Michel, Krebs, Marie-Odile, Scanferla, Elisabetta, Kishimoto, Taishiro, Rabbani, Golam, Skonieczna-Żydecka, Karolina, Brambilla, Paolo, Favaro, Angela, Takamiya, Akihiro, Zoccante, Leonardo, Colizzi, Marco, Bourgin, Julie, Kamiński, Karol, Moghadasin, Maryam, Seedat, Soraya, Matthews, Evan, Wells, John, Vassilopoulou, Emilia, Gadelha, Ary, Su, Kuan-Pin, Kwon, Jun Soo, Kim, Minah, Lee, Tae Young, Papsuev, Oleg, Manková, Denisa, Boscutti, Andrea, Gerunda, Cristiano, Saccon, Diego, Righi, Elena, Monaco, Francesco, Croatto, Giovanni, Cereda, Guido, Demurtas, Jacopo, Brondino, Natascia, Veronese, Nicola, Enrico, Paolo, Politi, Pierluigi, Ciappolino, Valentina, Pfennig, Andrea, Bechdolf, Andreas, Meyer-Lindenberg, Andreas, Kahl, Kai, Domschke, Katharina, Bauer, Michael, Koutsouleris, Nikolaos, Winter, Sibylle, Borgwardt, Stefan, Bitter, Istvan, Balazs, Judit, Czobor, Pal, Unoka, Zsolt, Mavridis, Dimitris, Tsamakis, Konstantinos, Bozikas, Vasilios, Tunvirachaisakul, Chavit, Maes, Michael, Rungnirundorn, Teerayuth, Supasitthumrong, Thitiporn, Haque, Ariful, Brunoni, Andre, Costardi, Carlos Gustavo, Schuch, Felipe Barreto, Polanczyk, Guilherme, Luiz, Jhoanne Merlyn, Fonseca, Lais, Aparicio, Luana, Valvassori, Samira, Nordentoft, Merete, Vendsborg, Per, Hoffmann, Sofie Have, Sehli, Jihed, Sartorius, Norman, Heuss, Sabina, Guinart, Daniel, Hamilton, Jane, Kane, John, Rubio, Jose, Sand, Michael, Koyanagi, Ai, Solanes, Aleix, Andreu-Bernabeu, Alvaro, Cáceres, Antonia San José, Arango, Celso, Díaz-Caneja, Covadonga, Hidalgo-Mazzei, Diego, Vieta, Eduard, Gonzalez-Peñas, Javier, Fortea, Lydia, Parellada, Mara, Fullana, Miquel, Verdolini, Norma, Fárková, Eva, Janků, Karolina, Millan, Mark, Honciuc, Mihaela, Moniuszko-Malinowska, Anna, Łoniewski, Igor, Samochowiec, Jerzy, Kiszkiel, Łukasz, Marlicz, Maria, Sowa, Paweł, Marlicz, Wojciech, Spies, Georgina, Stubbs, Brendon, Firth, Joseph, Sullivan, Sarah, Darcin, Asli Enez, Aksu, Hatice, Dilbaz, Nesrin, Noyan, Onur, Kitazawa, Momoko, Kurokawa, Shunya, Tazawa, Yuki, Anselmi, Alejandro, Cracco, Cecilia, Machado, Ana Inés, Estrade, Natalia, de Leo, Diego, Curtis, Jackie, Berk, Michael, Ward, Philip, Teasdale, Scott, Rosenbaum, Simon, Marx, Wolfgang, Horodnic, Adrian Vasile, Oprea, Liviu, Alexinschi, Ovidiu, Ifteni, Petru, Turliuc, Serban, Ciuhodaru, Tudor, Bolos, Alexandra, Matei, Valentin, Nieman, Dorien, Sommer, Iris, van Os, Jim, van Amelsvoort, Therese, Sun, Ching-Fang, Guu, Ta-Wei, Jiao, Can, Zhang, Jieting, Fan, Jialin, Zou, Liye, Yu, Xin, Chi, Xinli, de Timary, Philippe, van Winke, Ruud, Ng, Bernardo, Pena, Edilberto, Arellano, Ramon, Roman, Raquel, Sanchez, Thelma, Movina, Larisa, Morgado, Pedro, Brissos, Sofia, Aizberg, Oleg, Mosina, Anna, Krinitski, Damir, Mugisha, James, Sadeghi-Bahmani, Dena, Sadeghi, Masoud, Hadi, Samira, Brand, Serge, Errazuriz, Antonia, Crossley, Nicolas, Ristic, Dragana Ignjatovic, López-Jaramillo, Carlos, Efthymiou, Dimitris, Kuttichira, Praveenlal, Kallivayalil, Roy Abraham, Javed, Afzal, Afridi, Muhammad Iqbal, James, Bawo, Seb-Akahomen, Omonefe Joy, Fiedorowicz, Jess, Carvalho, Andre, Daskalakis, Jeff, Yatham, Lakshmi, Yang, Lin, Okasha, Tarek, Dahdouh, Aïcha, Gerdle, Björn, Tiihonen, Jari, Shin, Jae Il, Lee, Jinhee, Mhalla, Ahmed, Gaha, Lotfi, Brahim, Takoua, Altynbekov, Kuanysh, Negay, Nikolay, Nurmagambetova, Saltanat, Jamei, Yasser Abu, Weiser, Mark, Correll, Christoph, Thygesen, Lau, Kwon, Jun, Lee, Tae, Costardi, Carlos, Schuch, Felipe, Luiz, Jhoanne, Hoffmann, Sofie, Cáceres, Antonia, Darcin, Asli, Machado, Ana, Horodnic, Adrian, Ristic, Dragana, Kallivayalil, Roy, Afridi, Muhammad, Seb-Akahomen, Omonefe, Shin, Jae, Jamei, Yasser, RS: MHeNs - R2 - Mental Health, Psychiatrie & Neuropsychologie, MUMC+: MA Med Staf Spec Psychiatrie (9), Clinical Cognitive Neuropsychiatry Research Program (CCNP), Movement Disorder (MD), Solmi, M., Estradé, A., Thompson, T., Agorastos, A., Radua, J., Cortese, S., Dragioti, E., Leisch, F., Vancampfort, D., Thygesen, L.C., Aschauer, H., Schloegelhofer, M., Akimova, E., Schneeberger, A., Huber, C.G., Hasler, G., Conus, P., Cuénod, K.Q.D., von Känel, R., Arrondo, G., Fusar-Poli, P., Gorwood, P., Llorca, P.-M., Krebs, M.-O., Scanferla, E., Kishimoto, T., Rabbani, G., Skonieczna-Żydecka, K., Brambilla, P., Favaro, A., Takamiya, A., Zoccante, L., Colizzi, M., Bourgin, J., Kamiński, K., Moghadasin, M., Seedat, S., Matthews, E., Wells, J., Vassilopoulou, E., Gadelha, A., Su, K.-P., Kwon, J.S., Kim, M., Lee, T.Y., Papsuev, O., Manková, D., Boscutti, A., Gerunda, C., Saccon, D., Righi, E., Monaco, F., Croatto, G., Cereda, G., Demurtas, J., Brondino, N., Veronese, N., Enrico, P., Politi, P., Ciappolino, V., Pfennig, A., Bechdolf, A., Meyer-Lindenberg, A., Kahl, K.G., Domschke, K., Bauer, M., Koutsouleris, N., Winter, S., Borgwardt, S., Bitter, I., Balazs, J., Czobor, P., Unoka, Z., Mavridis, D., Tsamakis, K., Bozikas, V.P., Tunvirachaisakul, C., Maes, M., Rungnirundorn, T., Supasitthumrong, T., Haque, A., Brunoni, A.R., Costardi, C.G., Schuch, F.B., Polanczyk, G., Luiz, J.M., Fonseca, L., Aparicio, L.V., Valvassori, S.S., Nordentoft, M., Vendsborg, P., Hoffmann, S.H., Sehli, J., Sartorius, N., Heuss, S., Guinart, D., Hamilton, J., Kane, J., Rubio, J., Sand, M., Koyanagi, A., Solanes, A., Andreu-Bernabeu, A., Cáceres, A.S.J., Arango, C., Díaz-Caneja, C.M., Hidalgo-Mazzei, D., Vieta, E., Gonzalez-Peñas, J., Fortea, L., Parellada, M., Fullana, M.A., Verdolini, N., Fárková, E., Janků, K., Millan, M., Honciuc, M., Moniuszko-Malinowska, A., Łoniewski, I., Samochowiec, J., Kiszkiel, Ł., Marlicz, M., Sowa, P., Marlicz, W., Spies, G., Stubbs, B., Firth, J., Sullivan, S., Darcin, A.E., Aksu, H., Dilbaz, N., Noyan, O., Kitazawa, M., Kurokawa, S., Tazawa, Y., Anselmi, A., Cracco, C., Machado, A.I., Estrade, N., De Leo, D., Curtis, J., Berk, M., Ward, P., Teasdale, S., Rosenbaum, S., Marx, W., Horodnic, A.V., Oprea, L., Alexinschi, O., Ifteni, P., Turliuc, S., Ciuhodaru, T., Bolos, A., Matei, V., Nieman, D.H., Sommer, I., van Os, J., van Amelsvoort, T., Sun, C.-F., Guu, T.-W., Jiao, C., Zhang, J., Fan, J., Zou, L., Yu, X., Chi, X., de Timary, P., van Winke, R., Ng, B., Pena, E., Arellano, R., Roman, R., Sanchez, T., Movina, L., Morgado, P., Brissos, S., Aizberg, O., Mosina, A., Krinitski, D., Mugisha, J., Sadeghi-Bahmani, D., Sadeghi, M., Hadi, S., Brand, S., Errazuriz, A., Crossley, N., Ristic, D.I., López-Jaramillo, C., Efthymiou, D., Kuttichira, P., Kallivayalil, R.A., Javed, A., Afridi, M.I., James, B., Seb-Akahomen, O.J., Fiedorowicz, J., Carvalho, A.F., Daskalakis, J., Yatham, L.N., Yang, L., Okasha, T., Dahdouh, A., Gerdle, B., Tiihonen, J., Shin, J.I., Lee, J., Mhalla, A., Gaha, L., Brahim, T., Altynbekov, K., Negay, N., Nurmagambetova, S., Jamei, Y.A., Weiser, M., Correll, C.U., Adult Psychiatry, APH - Mental Health, ANS - Compulsivity, Impulsivity & Attention, ANS - Mood, Anxiety, Psychosis, Stress & Sleep, Martinez Rico, Clara, Clinique des maladies mentales et de l'encéphale (CMME - Service de psychiatrie), Hôpital Sainte-Anne-Université Paris Cité (UPCité), GHU Paris Psychiatrie et Neurosciences, Institut de psychiatrie et neurosciences de Paris (IPNP - U1266 Inserm), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), CHU Clermont-Ferrand, Pathologies et épithéliums : prévention, innovation, traitements, évaluation (UR 4267) (PEPITE), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)

Subjects
Gerontology, DISORDER, [SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Psychological intervention, Physical health, Adolescents, HV, Children, Covid-19, Mental health, Pandemic, Resilience, RA0421, Medicine, Adolescent, Adult, Child, Cross-Sectional Studies, Health Promotion, Humans, Mental Health, Pandemics, Quality of Life, SARS-CoV-2, COVID-19, SCALE, media_common, Psychiatry, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Public Health, Global Health, Social Medicine and Epidemiology, Psychiatry and Mental health, Clinical Psychology, Professional association, Psychological resilience, Life Sciences & Biomedicine, Psychopathology, Covid-19, Pandemic, Mental health, Physical health, Resilience, Children, Adolescents, media_common.quotation_subject, Clinical Neurology, BF, Article, Quality of life (healthcare), Intervention (counseling), VALIDITY, Science & Technology, business.industry, Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi, [SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health, Neurosciences & Neurology, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

BACKGROUND: The COVID-19 pandemic has altered daily routines and family functioning, led to closing schools, and dramatically limited social interactions worldwide. Measuring its impact on mental health of vulnerable children and adolescents is crucial. METHODS: The Collaborative Outcomes study on Health and Functioning during Infection Times (COH-FIT - www.coh-fit.com) is an on-line anonymous survey, available in 30 languages, involving >230 investigators from 49 countries supported by national/international professional associations. COH-FIT has thee waves (until the pandemic is declared over by the WHO, and 6-18 months plus 24-36 months after its end). In addition to adults, COH-FIT also includes adolescents (age 14-17 years), and children (age 6-13 years), recruited via non-probability/snowball and representative sampling and assessed via self-rating and parental rating. Non-modifiable/modifiable risk factors/treatment targets to inform prevention/intervention programs to promote health and prevent mental and physical illness in children and adolescents will be generated by COH-FIT. Co-primary outcomes are changes in well-being (WHO-5) and a composite psychopathology P-Score. Multiple behavioral, family, coping strategy and service utilization factors are also assessed, including functioning and quality of life. RESULTS: Up to June 2021, over 13,000 children and adolescents from 59 countries have participated in the COH-FIT project, with representative samples from eleven countries. LIMITATIONS: Cross-sectional and anonymous design. CONCLUSIONS: Evidence generated by COH-FIT will provide an international estimate of the COVID-19 effect on children's, adolescents' and families', mental and physical health, well-being, functioning and quality of life, informing the formulation of present and future evidence-based interventions and policies to minimize adverse effects of the present and future pandemics on youth. ispartof: JOURNAL OF AFFECTIVE DISORDERS vol:299 pages:367-376 ispartof: location:Netherlands status: published

Published
2022
Full Text
View/download PDF

38. Changes in triglyceride levels in ultra-high risk for psychosis individuals treated with omega-3 fatty acids.

Author

Mossaheb N, Papageorgiou K, Schäfer MR, Becker J, Schloegelhofer M, and Amminger GP

Subjects
Adolescent, Adult, C-Reactive Protein metabolism, Double-Blind Method, Fatty Acids, Omega-3 therapeutic use, Female, Humans, Male, Psychotic Disorders diagnosis, Psychotic Disorders diet therapy, Psychotic Disorders metabolism, Young Adult, Fatty Acids, Omega-3 pharmacology, Prodromal Symptoms, Psychotic Disorders blood, Triglycerides blood
Abstract

Aim: The aim of this analysis was to assess changes in lipid parameters, specifically in triglyceride (TG) levels, in a population at ultra-high risk (UHR) for psychosis treated with ω-3 polyunsaturated fatty acids (PUFAs) versus placebo., Methods: Data were derived from a randomized, double-blind, placebo-controlled trial conducted at an early psychosis unit. Eighty-one individuals, aged 13-25 years, at UHR for psychosis participated in a 12-week intervention trial of 1.2 g/day of ω-3 PUFAs (n = 41) versus placebo (n = 40). Lipid and C-reactive protein levels were collected at baseline and after 12 weeks., Results: Between-group comparisons showed no significant difference in TG levels after the intervention. However, in individuals with baseline TG levels above 150 mg dL -1 there was a significant mean TG reduction of 67.29 (SD 42.54; P = 0.006) in the ω-3 group (n = 7)., Conclusion: In this sample of UHR individuals, a 12-week intervention with ω-3 PUFAs was effective in reducing previously elevated TG levels. This might introduce the possibility of altering the lipid profile and thus the risk of cardiovascular morbidity of UHR individuals., (© 2015 Wiley Publishing Asia Pty Ltd.)

Published
2018
Full Text
View/download PDF

39. Usefulness of the CAPE-P15 for detecting people at ultra-high risk for psychosis: Psychometric properties and cut-off values.

Author

Bukenaite A, Stochl J, Mossaheb N, Schäfer MR, Klier CM, Becker J, Schloegelhofer M, Papageorgiou K, Montejo AL, Russo DA, Jones PB, Perez J, and Amminger GP

Subjects
Adolescent, Female, Humans, Male, Models, Theoretical, Psychiatric Status Rating Scales, Reproducibility of Results, Risk Factors, Self Report, Psychometrics, Psychotic Disorders diagnosis, Psychotic Disorders psychology
Abstract

A need for a brief, easy to complete self-report questionnaire to detect people at ultra-high risk for psychosis (UHR) in busy clinical settings has been recognised. Our aim was to explore whether the Community Assessment of Psychic Experiences - Positive 15-items Scale (CAPE-P15) could be used as a screening tool to identify people at UHR in a clinical setting. Our objectives were to confirm the CAPE-P15 factorial structure as well as its reliability and determine cut-off values for the detection of such individuals using the Comprehensive Assessment of At-Risk Mental States (CAARMS), a commonly used clinical interview for the detection of UHR. 165 participants aged between 13 and 18 referred to the General Hospital of Vienna were included in the analysis. 50.9% of the sample were "CAARMS-positive" and 49.1% "CAARMS-negative". The Youden method determined CAPE-P15 cut-off values for UHR detection of 1.47 for both frequency of and distress associated with psychotic experiences. The cut-off value of 1.47 for frequency showed sensitivity of 77%, specificity of 58%, a positive predictive value of 66% and a negative predictive value of 71%; whilst for distress it showed sensitivity of 73%, specificity of 63%, a positive predictive value of 69% and a negative predictive value of 66%. Good reliability and the previously suggested three-correlated factor model as well as an alternative bi-factor model of the CAPE-P15 were confirmed. The CAPE-P15 seems to be a promising screening tool for identifying people who might be at UHR in busy clinical settings., (Copyright © 2017 Elsevier B.V. All rights reserved.)

Published
2017
Full Text
View/download PDF

40. Rare Copy Number Variants in NRXN1 and CNTN6 Increase Risk for Tourette Syndrome.

Author

Huang AY, Yu D, Davis LK, Sul JH, Tsetsos F, Ramensky V, Zelaya I, Ramos EM, Osiecki L, Chen JA, McGrath LM, Illmann C, Sandor P, Barr CL, Grados M, Singer HS, Nöthen MM, Hebebrand J, King RA, Dion Y, Rouleau G, Budman CL, Depienne C, Worbe Y, Hartmann A, Müller-Vahl KR, Stuhrmann M, Aschauer H, Stamenkovic M, Schloegelhofer M, Konstantinidis A, Lyon GJ, McMahon WM, Barta C, Tarnok Z, Nagy P, Batterson JR, Rizzo R, Cath DC, Wolanczyk T, Berlin C, Malaty IA, Okun MS, Woods DW, Rees E, Pato CN, Pato MT, Knowles JA, Posthuma D, Pauls DL, Cox NJ, Neale BM, Freimer NB, Paschou P, Mathews CA, Scharf JM, and Coppola G

Subjects
Adolescent, Adult, Calcium-Binding Proteins, Case-Control Studies, Child, Female, Genetic Predisposition to Disease, Genome-Wide Association Study, Genotype, Humans, Male, Neural Cell Adhesion Molecules, Odds Ratio, White People genetics, Young Adult, Cell Adhesion Molecules, Neuronal genetics, Contactins genetics, DNA Copy Number Variations, Nerve Tissue Proteins genetics, Tourette Syndrome genetics
Abstract

Tourette syndrome (TS) is a model neuropsychiatric disorder thought to arise from abnormal development and/or maintenance of cortico-striato-thalamo-cortical circuits. TS is highly heritable, but its underlying genetic causes are still elusive, and no genome-wide significant loci have been discovered to date. We analyzed a European ancestry sample of 2,434 TS cases and 4,093 ancestry-matched controls for rare (< 1% frequency) copy-number variants (CNVs) using SNP microarray data. We observed an enrichment of global CNV burden that was prominent for large (> 1 Mb), singleton events (OR = 2.28, 95% CI [1.39-3.79], p = 1.2 × 10 -3 ) and known, pathogenic CNVs (OR = 3.03 [1.85-5.07], p = 1.5 × 10 -5 ). We also identified two individual, genome-wide significant loci, each conferring a substantial increase in TS risk (NRXN1 deletions, OR = 20.3, 95% CI [2.6-156.2]; CNTN6 duplications, OR = 10.1, 95% CI [2.3-45.4]). Approximately 1% of TS cases carry one of these CNVs, indicating that rare structural variation contributes significantly to the genetic architecture of TS., (Copyright © 2017 Elsevier Inc. All rights reserved.)

Published
2017
Full Text
View/download PDF

41. Brain-derived neurotrophic factor (BDNF)-epigenetic regulation in unipolar and bipolar affective disorder.

Author

Carlberg L, Scheibelreiter J, Hassler MR, Schloegelhofer M, Schmoeger M, Ludwig B, Kasper S, Aschauer H, Egger G, and Schosser A

Subjects
Adult, CpG Islands, Exons, Female, Genotype, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide, Promoter Regions, Genetic, Bipolar Disorder genetics, Brain-Derived Neurotrophic Factor genetics, DNA Methylation, Depressive Disorder, Major genetics, Epigenesis, Genetic
Abstract

Background: Alterations of brain-derived neurotrophic factor (BDNF) DNA methylation at specific BDNF promoters and corresponding gene expressions are associated with pathology and the response to antidepressant (AD) therapy in affective disorders such as major depressive disorder (MDD) and bipolar disorder (BD)., Methods: Genomic DNA was derived from peripheral blood mononuclear cells (PBMCs) and was bisulfite converted. Percentage of methylated reference (PMR) was calculated based on results from quantitative real-time PCR following the MethyLight protocol. For statistical analysis parametric procedures were performed as appropriate., Results: In this study 544 subjects were included, 207 MDD subjects, 59 BD subjects and 278 control subjects. The BDNF exon I promoter methylation resulted to be significantly increased in MDD subjects compared to BD subjects (p=0.0089) and control subjects (p<0.001). Furthermore, the increase of methylation in MDD subjects was significantly associated with AD therapy (p=0.0019) but not to the clinical features of depression such as the severity of symptoms (p=n.s.). None of the 12 investigated single nucleotide polymorphisms (SNP) showed significant genotype-methylation interactions., Limitations: Although based on previous findings, the DNA methylation was evaluated within only one CpG island of the different alternative BDNF gene transcripts., Conclusions: The results suggest that the methylation status might not only be affected by the disease phenotype but might also be further influenced by pharmacological treatment, therefore harbouring the possibility of identifying new insights for treatment options., (Copyright © 2014. Published by Elsevier B.V.)

Published
2014
Full Text
View/download PDF

42. Genetic association signal near NTN4 in Tourette syndrome.

Author

Paschou P, Yu D, Gerber G, Evans P, Tsetsos F, Davis LK, Karagiannidis I, Chaponis J, Gamazon E, Mueller-Vahl K, Stuhrmann M, Schloegelhofer M, Stamenkovic M, Hebebrand J, Noethen M, Nagy P, Barta C, Tarnok Z, Rizzo R, Depienne C, Worbe Y, Hartmann A, Cath DC, Budman CL, Sandor P, Barr C, Wolanczyk T, Singer H, Chou IC, Grados M, Posthuma D, Rouleau GA, Aschauer H, Freimer NB, Pauls DL, Cox NJ, Mathews CA, and Scharf JM

Subjects
Adult, Case-Control Studies, Humans, Netrins, Polymorphism, Single Nucleotide genetics, Genome-Wide Association Study statistics & numerical data, Nerve Growth Factors genetics, Tourette Syndrome genetics
Abstract

Tourette syndrome (TS) is a neurodevelopmental disorder with a complex genetic etiology. Through an international collaboration, we genotyped 42 single nucleotide polymorphisms (p < 10(-3) ) from the recent TS genomewide association study (GWAS) in 609 independent cases and 610 ancestry-matched controls. Only rs2060546 on chromosome 12q22 (p = 3.3 × 10(-4) ) remained significant after Bonferroni correction. Meta-analysis with the original GWAS yielded the strongest association to date (p = 5.8 × 10(-7) ). Although its functional significance is unclear, rs2060546 lies closest to NTN4, an axon guidance molecule expressed in developing striatum. Risk score analysis significantly predicted case-control status (p = 0.042), suggesting that many of these variants are true TS risk alleles., (© 2014 American Neurological Association.)

Published
2014
Full Text
View/download PDF

43. Duration of untreated psychosis in a high-income versus a low- and middle-income region.

Author

Mossaheb N, Schloegelhofer M, Kaufmann RM, Werneck-Rohrer S, Zehetmayer S, Malik F, Khawar R, Chaudry HR, Amminger GP, Klier CM, and Aschauer H

Subjects
Adolescent, Adult, Austria, Culture, Female, Humans, Male, Pakistan, Psychotic Disorders diagnosis, Psychotic Disorders psychology, Socioeconomic Factors, Time Factors, Income, Poverty, Psychotic Disorders therapy
Abstract

Objective: Most data on duration of untreated psychosis (DUP) derives from high-income countries. An inverse relationship between DUP and income and a longer DUP in low- and middle-income (LAMI) countries has been reported. The aim of this study was to compare DUP in a high-income country with that in a LAMI country using the same methodology., Methods: The sample consisted of in- and outpatients, aged 15-35 years for the Vienna site and 18-35 years for the Pakistani sites, with first-episode psychosis (FEP). DUP was evaluated using psychiatric interviews, medical charts and the Nottingham Onset Schedule. Differentiated reporting of duration of untreated illness (DUI) from prodrome to start of treatment, and DUP from manifest psychotic symptoms to start of treatment was ensured. Primary outcome measures, DUI and DUP, were measured at a 0.025 level of significance., Results: Thirty-one FEP patients in Vienna (mean age 20.03 years, SD 4.2) and 60 FEP patients from the Pakistani sites (mean age 26.15 years, SD 5.29) participated. The mean age in Vienna was younger due to the different age range inclusion criteria. The severity of psychopathology was more pronounced in the Pakistani sample. Log DUP was significantly different between groups (i.e. longer in the Pakistani sample (p=0.001)). Log DUI showed a trend for longer duration in the Vienna sample; however, this did not reach statistical significance (p=0.036). The severity of positive psychotic symptoms was associated with length of DUI in both regions., Conclusion: The longer DUP in Pakistan confirms the need to provide affordable treatment for psychosis for young FEP patients in Pakistan and in other LAMI countries. The relatively long period from prodrome to treatment initiation in both regions underlines the need to further establish low-threshold early intervention strategies in order to increase detection rates and reduce factors limiting patients seeking treatment.

Published
2013
Full Text
View/download PDF

44. The Community Assessment of Psychic Experience (CAPE) questionnaire as a screening-instrument in the detection of individuals at ultra-high risk for psychosis.

Author

Mossaheb N, Becker J, Schaefer MR, Klier CM, Schloegelhofer M, Papageorgiou K, and Amminger GP

Subjects
Adolescent, Female, Humans, Male, ROC Curve, Risk Factors, Self Report, Young Adult, Psychiatric Status Rating Scales, Psychotic Disorders diagnosis, Psychotic Disorders psychology, Risk Assessment, Surveys and Questionnaires
Abstract

Recent findings on intervention options in individuals at ultra-high risk (UHR) for psychosis underline the necessity of a screening tool that facilitates early detection in low-threshold, non-specialized settings. The aim of this study was to examine, whether the Community Assessment of Psychic Experience (CAPE) could be used as a screening tool to detect individuals at an increased risk for developing psychosis in a clinical, help-seeking population. The utility of the CAPE was assessed against the Comprehensive Assessment of At-Risk Mental States (CAARMS). The CAPE is a 42-item self-report questionnaire that proved to be stable, reliable and valid for self reported psychotic-like experiences in the general population. 165 individuals between 13 and 24years of age were assessed for being at UHR for developing psychosis. 50.9% individuals were CAARMS-positive and 49.1% were CAARMS-negative. The ROC-analysis provided two cut-off points: The cut-off value of 3.20 in the positive dimension showed a sensitivity of 67%, a specificity of 73%, a positive predictive value of 72% and a negative predictive value of 68%. The cut-off value of 2.80 in the positive dimension showed a higher sensitivity (83%) and a better negative predictive value (74%), but a lower specificity (49%) and a reduced positive predictive value (63%). Our results show promise that the CAPE is a valid, simple and cost-effective instrument for detecting individuals at UHR in a clinical population. It may represent a useful screening tool for calling clinicians' attention to subjects with psychotic-like experiences., (Copyright © 2012 Elsevier B.V. All rights reserved.)

Published
2012
Full Text
View/download PDF

45. Polyunsaturated fatty acids in emerging psychosis.

Author

Mossaheb N, Schloegelhofer M, Schaefer MR, Fusar-Poli P, Smesny S, McGorry P, Berger G, and Amminger GP

Subjects
Early Diagnosis, Fatty Acids, Omega-3 metabolism, Fatty Acids, Omega-3 therapeutic use, Humans, Psychotic Disorders diagnosis, Randomized Controlled Trials as Topic methods, Fatty Acids, Unsaturated metabolism, Fatty Acids, Unsaturated therapeutic use, Psychotic Disorders drug therapy, Psychotic Disorders metabolism
Abstract

The role of polyunsaturated fatty acids and their metabolites for the cause and treatment of psychotic disorders are widely discussed. The efficacy as an augmenting agent in chronic schizophrenia seems to be small or not present, however epidemiological data, as well as some recent controlled studies in emerging psychosis point towards possible preventive effects of long-chain polyunsaturated fatty acids in early and very early stages of psychotic disorders and some potential secondary or tertiary beneficial long-term effects in later, more chronic stages, in particular for metabolic or extra-pyramidal side effects. In this comprehensive review, we describe the physiology and metabolism of polyunsaturated fatty acids, phospholipases, epidemiological evidence and the effect of these fatty acids on the brain and neurodevelopment. Furthermore, we examine the available evidence in indicated prevention in emerging psychosis, monotherapy, add-on therapy and tolerability. The neuroprotective potential of n-3 LC-PUFAs for indicated prevention, i.e. delaying transition to psychosis in high-risk populations needs to be further explored.

Published
2012
Full Text
View/download PDF

46. Bipolar disorder susceptibility region on chromosome 3q29 not confirmed in a case-control association study.

Author

Schosser A, Schloegelhofer M, Fuchs K, Stojanovic M, Mossaheb N, Kindler J, Cohen-Woods S, Hosang G, Farmer A, Craig I, McGuffin P, and Aschauer H

Subjects
Case-Control Studies, Chromosome Mapping methods, Female, Genetic Predisposition to Disease genetics, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide genetics, Bipolar Disorder genetics, Chromosomes, Human, Pair 3 genetics
Abstract

Objectives: We identified a bipolar disorder (BPD) susceptibility region on chromosome 3q29 in a genome-wide linkage scan (Bailer et al. 2002 (Biol Psychiatry 52: 40), NPL-score 4.09) and follow-up linkage analysis (Schosser et al. 2004 (J Psychiatr Res 38(3): 357), NPL-scores >3 with five markers). These findings were supported by further fine-mapping of this region (Schosser et al. 2007 (Eur Neuropsychopharmacol 17(6-7): 501)), finding NPL-scores >3.9 with SNPs (single nucleotide polymorphisms) spanning a region of 3.46 Mbp in BPD families. Since genetic association studies are more powerful than linkage studies for detecting susceptibility genes of small effect size, we aimed to replicate these findings in an independent case-control sample collected in London (UK) and Vienna (Austria)., Methods: A total of 51 SNPs were genotyped using Sequenom MassARRAY(®) iPLEX Gold and tested for association in a sample of 526 cases suffering from DSM-IV and/or ICD-10 diagnosis of BPD and 691 controls., Results: No genotypic and/or allelic association, as well as no haplotypic association, was found for any SNP after multiple testing correction., Conclusions: However, we cannot exclude the possibility that our sample might not have the power to detect rare variants associated with susceptibility to BPD., (© 2011 Informa Healthcare)

Published
2011
Full Text
View/download PDF

47. Interaction between serotonin 5-HT2A receptor gene and dopamine transporter (DAT1) gene polymorphisms influences personality trait of persistence in Austrian Caucasians.

Author

Schosser A, Fuchs K, Scharl T, Schloegelhofer M, Kindler J, Mossaheb N, Kaufmann RM, Leisch F, Kasper S, Sieghart W, and Aschauer HN

Subjects
Adult, Alleles, Austria, Exploratory Behavior, Female, Genotype, Harm Reduction, Heterozygote, Homozygote, Humans, Male, Minisatellite Repeats genetics, Polymerase Chain Reaction, Polymorphism, Single Nucleotide genetics, Receptors, Dopamine D3 genetics, Sex Factors, Statistics, Nonparametric, White People psychology, Dopamine Plasma Membrane Transport Proteins genetics, Personality genetics, Polymorphism, Genetic genetics, Receptor, Serotonin, 5-HT2A genetics, White People genetics
Abstract

We examined 89 normal volunteers using Cloninger's Temperament and Character Inventory (TCI). Genotyping the 102T/C polymorphism of the serotonin 5HT2A receptor gene and the ser9gly polymorphism in exon 1 of the dopamine D3 receptor (DRD3) gene was performed using PCR-RFLP, whereas the dopamine transporter (DAT1) gene variable number of tandem repeats (VNTR) polymorphism was investigated using PCR amplification followed by electrophoresis in an 8% acrylamide gel with a set of size markers. We found a nominally significant association between gender and harm avoidance (P=0.017; women showing higher scores). There was no association of either DAT1, DRD3 or 5HT2A alleles or genotypes with any dimension of the TCI applying Kruskal-Wallis rank-sum tests. Comparing homozygote and heterozygote DAT1 genotypes, we found higher novelty seeking scores in homozygotes (P=0.054). We further found a nominally significant interaction between DAT1 and 5HT2A homo-/heterozygous gene variants (P=0.0071; DAT1 and 5HT2A genotypes P value of 0.05), performing multivariate analysis of variance (MANOVA). Examining the temperamental TCI subscales, this interaction was associated with persistence (genotypes: P=0.004; homo-/heterozygous gene variants: P=0.0004). We conclude that an interaction between DAT1 and 5HT2A genes might influence the temperamental personality trait persistence.

Published
2010
Full Text
View/download PDF

48. Tourette's syndrome is not associated with interleukin-10 receptor 1 variants on chromosome 11q23.3.

Author

Kindler J, Schosser A, Stamenkovic M, Schloegelhofer M, Leisch F, Hornik K, Aschauer H, and Gasche C

Subjects
Adult, Alleles, Autoantibodies immunology, Female, Genotype, Humans, Interleukin-10 Receptor alpha Subunit immunology, Male, Polymerase Chain Reaction, Tourette Syndrome immunology, Chromosomes, Human, Pair 11 genetics, Interleukin-10 Receptor alpha Subunit genetics, Tourette Syndrome genetics
Abstract

Interleukin-10 receptor 1 (IL-10R1) single nucleotide polymorphisms, located on chromosome 11q23 - a strong candidate for linkage with Tourette's syndrome (TS) - have been investigated for association with TS. DNA of 77 patients with a DSM-IV (Diagnostic and Statistical Manual IV) diagnosis of TS and 250 healthy controls was genotyped. IL-10R1 was not associated with TS.

Published
2008
Full Text
View/download PDF

49. Pharmacokinetics and elimination of quetiapine, venlafaxine, and trazodone during pregnancy and postpartum.

Author

Klier CM, Mossaheb N, Saria A, Schloegelhofer M, and Zernig G

Subjects
Adolescent, Antipsychotic Agents blood, Antipsychotic Agents pharmacokinetics, Antipsychotic Agents therapeutic use, Bipolar Disorder complications, Bipolar Disorder drug therapy, Bipolar Disorder metabolism, Cyclohexanols blood, Cyclohexanols therapeutic use, Dibenzothiazepines blood, Dibenzothiazepines therapeutic use, Female, Humans, Postpartum Period metabolism, Pregnancy, Pregnancy Outcome, Pregnancy Trimesters metabolism, Quetiapine Fumarate, Sleep Wake Disorders complications, Sleep Wake Disorders drug therapy, Sleep Wake Disorders metabolism, Trazodone blood, Trazodone therapeutic use, Venlafaxine Hydrochloride, Cyclohexanols pharmacokinetics, Dibenzothiazepines pharmacokinetics, Trazodone pharmacokinetics
Published
2007
Full Text
View/download PDF

50. Homozygosity of the interleukin-10 receptor 1 G330R allele is associated with schizophrenia.

Author

Schosser A, Aschauer HN, Wildenauer DB, Schwab SG, Albus M, Maier W, Schloegelhofer M, Leisch F, Hornik K, Murray SS, and Gasche C

Subjects
Alleles, Arginine genetics, Case-Control Studies, Female, Gene Frequency, Genetic Linkage, Genotype, Glycine genetics, Humans, Male, Models, Genetic, Homozygote, Interleukin-10 Receptor alpha Subunit genetics, Polymorphism, Single Nucleotide, Schizophrenia genetics
Abstract

Infections of unknown origin and an altered immune response have been hypothesized to play a role in the pathogenesis of schizophrenia. We have previously identified two single nucleotide polymorphisms (SNPs) of the IL-10 receptor 1 (IL-10R1) causing a substitution of glycine 330 to arginine (G330R) and of serine 138 to glycine (S138G). A possible association between these IL-10R1 variants and schizophrenia has been investigated in the present study. DNA of 101 unrelated Austrian patients with a DSM-III-R (Diagnostic and Statistical Manual of Mental Disorders) consensus diagnosis of schizophrenia (n = 70) or schizoaffective disorder (n = 31) and DNA of 121 German schizophrenic patients (DSM-III-R) was analyzed for the presence of S138G and G330R by allele-specific multiplex PCRs. Data from patients were compared with 250 unrelated, psychiatric healthy controls. No difference in allele frequency was detected between patients and controls (G330R: 34.0% vs. 30.0%, P = 0.208; S138G: 19.7% vs. 16.6%, P = 0.235; by Fisher's exact test). However, there was a significant difference in genotype distribution (wt/wt, wt/mut, mut/mut) for G330R between patients (46.8%, 38.3%, 14.9%) and controls (47.6%, 44.8%, 7.6%; Fisher's test P = 0.032). No such difference was seen for S138G. Our results suggest that homozygosity of the IL-10R1 G330R allele is associated with schizophrenia and may contribute to the expression of disease phenotype in susceptible individuals., ((c) 2006 Wiley-Liss, Inc.)

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results